By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Mdd Us Company Profile
Email this page to a colleague
What is the competitive landscape for MDD US, and what generic alternatives to MDD US drugs are available?
MDD US has two approved drugs.
There are three US patents protecting MDD US drugs.
There are eighty patent family members on MDD US drugs in thirty-one countries and eleven supplementary protection certificates in ten countries.
Summary for Mdd Us
| International Patents: | 80 |
| US Patents: | 3 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Mdd Us
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | Get Started Free | Get Started Free | |||||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | Get Started Free | Get Started Free | |||||
| Mdd Us | APOKYN | apomorphine hydrochloride | INJECTABLE;SUBCUTANEOUS | 021264-002 | Apr 20, 2004 | RX | Yes | Yes | Get Started Free | Get Started Free | |||||
| Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | 8,278,485 | Get Started Free | Y | Get Started Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Mdd Us Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20140027563 | Get Started Free |
| Brazil | PI0712936 | Get Started Free |
| Mexico | PA05010873 | Get Started Free |
| Eurasian Patent Organization | 017123 | Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mdd Us Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1613296 | CR 2015 00042 | Denmark | Get Started Free | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
| 1613296 | C 2015 034 | Romania | Get Started Free | PRODUCT NAME: SAFINAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/14/984; DATE OF NATIONAL AUTHORISATION: 20150224; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/984; DATE OF FIRST AUTHORISATION IN EEA: 20150224 |
| 1613296 | 92782 | Luxembourg | Get Started Free | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
| 1613296 | 15C0054 | France | Get Started Free | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
